@Cataceous, I definitely think you are correct that Xyosted has different pharmacokinetics compared with other forms of enanthate. But, I was thinking about the phase II study they published in 2015. I am not sure how to post papers, but the title is:
Pharmacokinetic Profile of Subcutaneous Testosterone
Enanthate Delivered via a Novel, Prefilled Single-Use Autoinjector: A Phase II Study
In this study, they show a graph in which the peak levels with 50mg stay the same over six weeks, and they state: "The 50-mg dose exhibited no accumulation between doses...
suggesting that clearance exceeds exposure by the end of the dosing interval
". I would assume that if the half life were 7 days or less, that the peaks would gradually rise, or is this flawed thinking? I also finding it a little odd that, if this is true, they even offer 50mg. Why would someone want troughs that land them in the same sub therapeutic range every week?
Their website claims that the peaks and troughs stay in a 1.8x ratio with each other, suggesting peaks are nearly double the trough levels. So, if your trough is 500, you peak should be around 900. Does anyone know if this therapeutic window is tighter than other esters, or is it similar?